Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04661007
Other study ID # INCMOR 0208-102
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date December 15, 2020
Est. completion date July 20, 2026

Study information

Verified date June 2024
Source Incyte Corporation
Contact Incyte Biosciences Japan GK Development Operations Call Center
Phone +81 3-3507-5795
Email japan_clinicaltrials@incyte.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label, multicenter study to evaluate safety and tolerability, determine the RP2Ds of tafasitamab alone in Japanese participants with R/R NHL, or to evaluate efficacy and safety of tafasitamab in combination with lenalidomide in Japanese participants with R/R DLBCL, or tafasitimab in combination with lenalidomide plus R-CHOP in Japanese participants with previously untreated DLBC, or tafasitimab in combination with lenalidomide in Japanese participants with previously R/R DLBC.


Recruitment information / eligibility

Status Recruiting
Enrollment 65
Est. completion date July 20, 2026
Est. primary completion date May 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Group 1 only: Biopsy-proven participants with relapsed or refractory NHL of DLBCL, FL or MZL. - Groups 3, 4a and 5 only: Biopsy-proven participants with relapsed or refractory DLBCL. - Groups 2 and 6 only: Biopsy-proven participants with DLBCL and another select lymphoid neoplasms. - Participants must have at least 1 bi-dimensionally measurable lesion. - ECOG performance status of 0 to 2. - Participants with protocol defined laboratory criteria at screening as defined in the protocol. - Group 1 only: Received at least 1 previous systemic therapy line for the treatment of NHL. At least 1 previous therapy line must have included a CD20-targeted therapy (eg, RTX). - Groups 2, 3, 4a and 6 only: Received at least 1, but no more than 3, previous systemic therapy lines for the treatment of DLBCL. At least 1 previous therapy line must have included a CD20-targeted therapy (eg, RTX). - Group 5 only: Participants must have: 1. Untreated DLBCL. 2. Ann Arbor Stage III to IV. 3. IPI status of 3 to 5 or age-adjusted IPI 2-3 (in Group 5 only). 4. Appropriate candidate for R-CHOP. 5. LVEF of = 50%, assessed by echocardiography. - Willingness to avoid pregnancy or fathering children. - In the opinion of investigator, the participant must: 1. Not have a history of noncompliance in relation to medical regimens or be considered potentially unreliable and/or uncooperative. 2. Be able to understand the reason for complying with the special conditions of the pregnancy prevention risk management plan and give written acknowledgement of this. Exclusion Criteria: - Any other histological type of lymphoma. - History of prior non-hematologic malignancy. - Congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias. - Participants with known positive test result for hepatitis C, and hepatitis B. - Known seropositive for or history of active viral infection with HIV. - Known active bacterial, viral, fungal, mycobacterial, or other infection at screening. - Known CNS lymphoma involvement - present or past medical history. - History or evidence of clinically significant cardiovascular, CNS and/or other systemic disease that would in the investigator's opinion preclude participation in the study or compromise the participant's ability to give informed consent. - History or evidence of rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. - History or evidence of interstitial lung disease. - Vaccination with live vaccine within 21 days prior to study treatment (Note: throughout the study treatment period and at least 6 months after end of treatment, vaccination with live vaccines should be avoided). - Major surgery within up to 30 days prior to signing the ICF, unless the participant is recovered at the time of signing the ICF. - Any anticancer and/or investigational therapy within 14 days prior to the start of Cycle 1. - Groups 2, 3, 4a, 5 and 6 only: Gastrointestinal abnormalities including the inability to take oral study treatment, requiring IV alimentation, or prior surgical procedure affecting absorption. - Pregnancy or lactation. - Groups 2, 3, 5 and 6 only: Participants who have history of deep venous thrombosis/embolism, threatening thromboembolism, stroke or known thrombophilia or are at a high risk for a thromboembolic event in the opinion of the investigator and who are not willing/able to take venous thromboembolic event prophylaxis during the entire treatment period if required - Group 4a only: Use or expected use during the study of any restricted medications, including potent CYP3A4 inhibitors or inducers within 14 days or 5 half-lives (whichever is longer) before the date of study treatment administration - Groups 1, 3, 4a and 6 only: Participants who have: 1. Not discontinued CD20-targeted therapy, chemotherapy, radiotherapy, investigational anticancer therapy, or other lymphoma-specific therapy within the 14 days prior to Day 1 dosing. 2. In the opinion of the investigator, not recovered sufficiently from the adverse toxic effects of prior therapies. 3. Groups 1, 3 and 4a only: Previous treatment with CD19-targeted therapy (eg, CD19-CAR-T therapies, other CD19 mAbs including bispecific and ADCs). Groups 2 and 6 only: Previous treatment with tafasitamab. Note: Participants in Groups 2 and 6 who have received previous CD19 directed therapy (other than tafasitamab) must have CD19-positive lymphoma confirmed by a biopsy taken after completing the prior CD19-targeted therapy. 4. Groups 2, 3 and 6 only: Been previously treated with IMiDs (eg, thalidomide or LEN). 5. Group 4a only: Been previously treated with selective PI3Kd or pan-PI3K inhibitors (eg, idelalisib, copanlisib, duvelisib) and/or Bruton's tyrosine kinase inhibitors (eg, ibrutinib). 6. A history of hypersensitivity to compounds of similar biological or chemical composition to tafasitamab, IMiDs, and/or the excipients contained in the study treatment formulations (citric acid monohydrate, polysorbate 20, sodium citrate dehydrate and trehalose dihydrate). 7. Undergone ASCT within the period = 3 months before the signing of the ICF. Participants who have a more distant history of ASCT must exhibit full hematological recovery before enrolment into the study. 8. Undergone previous allogenic stem cell transplantation. 9. Concurrent treatment other anticancer or experimental treatments. - Group 5 only: Participants who have: 1. A history of radiation therapy to = 25% of the bone marrow for other diseases or history of anthracycline therapy. 2. A history of hypersensitivity or contraindication to any component of R-CHOP, LEN, or compounds of similar biological or chemical composition as tafasitamab and/or the excipients contained in the study treatment formulations or R-CHOP. 3. Contraindication to any of the individual components of R-CHOP. 4. Any anticancer and/or investigational therapy within 30 days prior to the start of Cycle 1, except for permitted prephase treatment defined below.

Study Design


Intervention

Drug:
tafasitamab
tafasitamab will be administered at protocol defined timepoints based on the groups participants are assigned.
lenalidomide
lenalidomide will be administered orally at protocol defined timepoints based on the groups participants are assigned.
parsaclisib
parsaclisib will be administered at protocol defined timepoints based on the groups participants are assigned.
R-CHOP
R-CHOP is a combination regimen consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. R-CHOP will be administered at protocol defined timepoints based on the groups participants are assigned.

Locations

Country Name City State
Japan Aichi Cancer Center Hospital Aichi
Japan Chiba Cancer Center Chiba
Japan National Cancer Center Hospital East Chiba
Japan University of Fukui Hospital Fukui
Japan Kyushu University Hospital Fukuoka
Japan National Hospital Organization Kyushu Cancer Center Fukuoka
Japan Tokai University Hospital Isehara
Japan Kobe City Medical Center General Hospital Kobe
Japan The Cancer Institute Hospital of Jfcr Koto-ku
Japan Nho Kumamoto Medical Center Kumamoto-ken
Japan Nho Shikoku Cancer Center Matsuyama
Japan Japanese Red Cross Nagoya Daini Hospital Nagoya
Japan Iuhw Narita Hospital Narita City
Japan Nho Okayama Medical Center Okayama
Japan Kindai University Hospital Osakasayama City
Japan Saitama Medical Center Saitama-shi
Japan Nho Hokkaido Cancer Center Sapporo
Japan Tohoku University Hospital Sendai-shi
Japan Osaka University Hospital Suita-shi
Japan Nho Disaster Medical Center Tachikawa
Japan National Cancer Center Hospital Tokyo
Japan Mie University Hospital TSU
Japan Kanagawa Cancer Center Yokohama-shi

Sponsors (1)

Lead Sponsor Collaborator
Incyte Biosciences Japan GK

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Part 1,2 and 3 : Treatment Emergent Adverse Events (TEAE'S) Adverse events reported for the first time or worsening of a pre-existing event after first dose of study treatment. Approximately 2 years
Primary Part 4: Objective Response Best Response of complete/complete metabolic response or partial/partial metabolic response Approximately 27 months
Secondary Part 1,2, 3 and 4 : Cmax of tafasitamab Maximum observed serum concentration. Approximately 27 months
Secondary Part 1, 2, 3 and 4: Cmin of tafasitamab Minimum observed serum concentration over the dose interval. Approximately 27 months
Secondary Part 4: Complete Response Defined as the proportion of participants with Complete Response as determined by an IRC and investigator assessment according to the Lugano criteria Approximately 27 months
Secondary Part 4: Duration of Response Defined as the time from the date of first documented evidence of CR or PR until the first documented disease progression or death from any cause, whichever occurs first, among participants who achieve an objective response as determined by IRC and investigator assessment based on the Lugano criteria for response assessment Approximately 27 months
Secondary Part 4: Progression-Free Survival Defined as the time from the date of randomization until the first documented disease progression as determined by IRC and investigator assessment based on the Lugano criteria for response assessment or death from any cause, whichever occurs first. Approximately 27 months
Secondary Part 4: Overall Survival Defined as the time from the date of randomization until death from any cause. Approximately 27 months
Secondary Part 4: Overall Response Rate Defined as the proportion of participants with a CR or PR as determined by the investigator based on the Lugano criteria for response assessment Approximately 27 months
Secondary Part 4: Treatment Emergent Adverse Events (TEAE'S) Adverse events reported for the first time or worsening of a pre-existing event after first dose of study treatment. Approximately 2 years
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT01804686 - A Long-term Extension Study of PCI-32765 (Ibrutinib) Phase 3
Recruiting NCT05823701 - Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients Phase 2
Completed NCT01691898 - A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) Phase 1/Phase 2
Recruiting NCT03656835 - Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma N/A
Terminated NCT02877082 - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Phase 2
Active, not recruiting NCT02060656 - Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND) Phase 2
Active, not recruiting NCT01653067 - STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma Phase 2
Enrolling by invitation NCT00846157 - Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients Phase 3
Completed NCT00440583 - The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP Phase 2
Completed NCT01851551 - Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL Phase 1/Phase 2
Recruiting NCT04981795 - realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL
Completed NCT01186978 - Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma N/A
Completed NCT01197560 - Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Phase 2/Phase 3
Recruiting NCT03246906 - Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation Phase 2
Not yet recruiting NCT05990985 - The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission. N/A
Completed NCT02890602 - Erythropoietin for Management of Anemia Caused by Chemotherapy Phase 2
Completed NCT03630159 - Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients Phase 1
Active, not recruiting NCT04529772 - A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) Phase 3
Active, not recruiting NCT02900651 - Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies Phase 1
Active, not recruiting NCT02481310 - Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma Phase 1/Phase 2